The estimated Net Worth of Charles Silberstein is at least $944 Tisíc dollars as of 8 June 2021. Dr Silberstein owns over 5,047 units of Applied Therapeutics stock worth over $457,454 and over the last 4 years he sold APLT stock worth over $108,107. In addition, he makes $378,197 as CFO & Head of Bus. Devel. at Applied Therapeutics.
Dr has made over 1 trades of the Applied Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 5,047 units of APLT stock worth $108,107 on 8 June 2021.
The largest trade he's ever made was selling 5,047 units of Applied Therapeutics stock on 8 June 2021 worth over $108,107. On average, Dr trades about 1,009 units every 0 days since 2020. As of 8 June 2021 he still owns at least 87,803 units of Applied Therapeutics stock.
You can see the complete history of Dr Silberstein stock trades at the bottom of the page.
Dr. Charles Silberstein M.D., CFA is the CFO & Head of Bus. Devel. at Applied Therapeutics.
As the CFO & Head of Bus. Devel. of Applied Therapeutics, the total compensation of Dr CFA at Applied Therapeutics is $378,197. There are 6 executives at Applied Therapeutics getting paid more, with shoshana Shendelman having the highest compensation of $11,590,000.
Dr CFA is 50, he's been the CFO & Head of Bus. Devel. of Applied Therapeutics since . There are 7 older and 3 younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics, Inc. is Jay Skyler, 73, who is the Independent Director.
Charles's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Over the last 6 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus a Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Applied Therapeutics executives and other stock owners filed with the SEC include: